Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.

Prostate specific antigen (PSA) test is the most common, clinically validated test for the diagnosis of prostate cancer (PCa). While neoplastic lesions of the prostate may cause aberrant levels of PSA in the blood, the quantitation of free or complexed PSA poorly discriminates cancer patients from those developing benign lesions, often leading to invasive and unnecessary surgical procedures. Microenvironmental acidity increases exosome release by cancer cells. In this study we evaluated whether acidity, a critical phenotype of malignancy, could influence exosome release and increase the PSA expression in nanovesicles released by PCa cells. To this aim, we exploited Nanoparticle Tracking Analysis (NTA), an immunocapture-based ELISA, and nanoscale flow-cytometry. The results show that microenvironmental acidity induces an increased release of nanovesicles expressing both PSA and the exosome marker CD81. In order to verify whether the changes induced by the local selective pressure of extracellular acidity may correspond to a clinical pathway we used the same approach to evaluate the levels of PSA-expressing exosomes in the plasma of PCa patients and controls, including subjects with benign prostatic hypertrophy (BPH). The results show that only PCa patients have high levels of nanovesicles expressing both CD81 and PSA. This study shows that tumor acidity exerts a selective pressure leading to the release of extracellular vesicles that express both PSA and exosome markers. A comparable scenario was shown in the plasma of prostate cancer patients as compared to both BPH and healthy controls. These results suggest that microenvironmental acidity may represent a key factor which determines qualitatively and quantitatively the release of extracellular vesicles by malignant tumors, including prostate cancer. This condition leads to the spill-over of nanovesicles into the peripheral blood of prostate cancer patients, where the levels of tumor biomarkers expressed by exosomes, such as PSA-exosomes, may represent a novel, non-invasive clinical tool for the screening and early diagnosis of prostate cancer.

[1]  T. D. de Reijke,et al.  Prostate cancer biomarker profiles in urinary sediments and exosomes. , 2014, The Journal of urology.

[2]  S. Fais,et al.  Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. , 2015, Cancer letters.

[3]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[4]  Graça Raposo,et al.  Exosomal-like vesicles are present in human blood plasma. , 2005, International immunology.

[5]  F. Petrucci,et al.  Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin , 2014, PloS one.

[6]  S. Fais,et al.  Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy , 2014, Cancer and Metastasis Reviews.

[7]  F. Lozupone,et al.  pH‐dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity , 2010, International journal of cancer.

[8]  M. Logozzi,et al.  Exosomes: the ideal nanovectors for biodelivery , 2013, Biological chemistry.

[9]  Alessia Ricupito,et al.  Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. , 2012, Cancer research.

[10]  P. Matarrese,et al.  Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. , 2007, Cancer research.

[11]  A. Llorente,et al.  Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line , 2004, Journal of Cell Science.

[12]  E. Feuer,et al.  Studies of prostate-cancer mortality: caution advised. , 2008, The Lancet. Oncology.

[13]  A. Molinari,et al.  Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells* , 2009, The Journal of Biological Chemistry.

[14]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[15]  M. Kesimer,et al.  Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. , 2012, Analytical biochemistry.

[16]  Francesco Cappello,et al.  Exosome levels in human body fluids: A tumor marker by themselves? , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  J. Lau,et al.  Active Surveillance in Men With Localized Prostate Cancer , 2012, Annals of Internal Medicine.

[18]  Carla Oliveira,et al.  Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. , 2016, ACS nano.

[19]  R. Hoffman,et al.  Clinical practice. Screening for prostate cancer. , 2011, The New England journal of medicine.

[20]  O. Brawley,et al.  Trends in prostate cancer in the United States. , 2012, Journal of the National Cancer Institute. Monographs.

[21]  Monique J. Roobol,et al.  Defining the threshold for significant versus insignificant prostate cancer , 2013, Nature Reviews Urology.

[22]  A. Lucas,et al.  Tumor Microenvironment Derived Exosomes Pleiotropically Modulate Cancer Cell 1 Metabolism 2 , 2016 .

[23]  G. Parmiani,et al.  Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. , 2005, Gastroenterology.

[24]  Licia Rivoltini,et al.  Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. , 2006, Cancer research.

[25]  H. Coller,et al.  Partners in the Warburg effect , 2016, eLife.

[26]  Massimo Spada,et al.  High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients , 2009, PloS one.

[27]  Joanne L Welton,et al.  Can urinary exosomes act as treatment response markers in prostate cancer? , 2009, Journal of Translational Medicine.

[28]  E. Iessi,et al.  Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. , 2016, Cancer letters.

[29]  Stefano Fais,et al.  Exosomes: the future of biomarkers in medicine. , 2013, Biomarkers in medicine.

[30]  H. Adami,et al.  Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort Study , 2009, PLoS medicine.

[31]  Natarajan Raghunand,et al.  In vivo imaging of extracellular pH using 1H MRSI , 1999, Magnetic resonance in medicine.

[32]  G. Ronquist,et al.  The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth , 2004, Prostate Cancer and Prostatic Diseases.

[33]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[34]  F. Lozupone,et al.  Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. , 2004, Journal of the National Cancer Institute.

[35]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[36]  L. O’Driscoll,et al.  Biological properties of extracellular vesicles and their physiological functions , 2015, Journal of extracellular vesicles.

[37]  Jason L. Townson,et al.  Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry , 2016, Oncotarget.

[38]  M. Amiji,et al.  Exosome mediated communication within the tumor microenvironment. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[39]  R. Canese,et al.  Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice , 2016, PloS one.

[40]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.